SANTA ROSA, Calif.--(BUSINESS WIRE)--Claret Medical® today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Sentinel™ Cerebral Protection ...

NEW YORK, NY—Yet again, use of the Sentinel cerebral protection system (Boston Scientific) has not been shown to significantly improve clinical outcomes for patients undergoing TAVI, according to the ...

MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection ...

SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

SANTA ROSA, Calif.--(BUSINESS WIRE)--Claret Medical® today announced that in an open public hearing of the FDA’s Circulatory System Devices Panel last week, virtually all panel members recommended the ...

WASHINGTON, DC—An exploratory analysis of the PROTECTED TAVR trial suggests that use of the Sentinel cerebral embolic protection system (Boston Scientific) during TAVI had a greater impact in patients ...

Heart device maker Boston Scientific Corp. has agreed to pay up to $270 million to acquire a California company called Claret Medical, which sells a temporary blood filter intended to prevent strokes ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW YORK CITY -- ...